Overview
Up take of tumor cells (green) coated with IgG (red) by monocytes and their load on MHCII molecules (purple).
Up take of tumor cells (green) coated with IgG (red) by dendritic cells and their load on MHC-II molecules (cyan).
Tumor cells coated with allogeneic IgG co-culture for overnight with monocytes
Up take of tumor cells (green) coated with IgG (red) by monocytes and their load on MHCII molecules (purple).
The goal of our lab is to provide a detailed understanding of the mechanisms, which regulate and control the discrimination between self and non-self, and thereby give rise to cytotoxic T cell immunity specifically directed against tumor targets. The ultimate goals of our research are embodied in the following specific aims:
​
-
What are the cellular and molecular elements that enable the immune system to recognize subtle antigenic variations from self to initiate a cytotoxic immune response?
-
How is the specificity of the induced immune response determined? In other words, what is the process by which the presentation of diverse antigens by DC translates to activation of specific effector T cells?
A more complete understanding of the means by which DC and T cells communicate to initiate antigen-restricted tumor immunity, will provide a roadmap for designing novel cancer immunotherapies with greater potency.
CONTACT US
Address:
The Department of Pathology
School of Medicine, Tel-Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel
​
Phone:
+972-3-640-9504
Emails
NEWS
January, 2017
Our manuscript - "Modeling effective cancer immunotherapy reveals the importance of systemic immunity" has been accepted for publication in Cell.
January, 2017
In a collaboration with Edgar Engleman the paper- "A novel subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes", has been accepted to PNAS
2016 The Carmi Lab: Cancer Immunobiology and Immunotherapy
The Department of Pathology, School of Medicine, Tel-Aviv University,
P.O. Box 39040, Tel Aviv 6997801, Israel